| Primary |
| Rheumatoid Arthritis |
23.0% |
| Acute Lymphocytic Leukaemia |
17.5% |
| Central Nervous System Lymphoma |
14.2% |
| Bone Sarcoma |
6.5% |
| Diffuse Large B-cell Lymphoma |
5.8% |
| Adult T-cell Lymphoma/leukaemia |
4.7% |
| Product Used For Unknown Indication |
4.3% |
| T-cell Lymphoma |
3.1% |
| Acute Myeloid Leukaemia |
2.6% |
| Chemotherapy |
2.1% |
| Hodgkin's Disease |
2.1% |
| Immunodeficiency |
2.1% |
| Burkitt's Lymphoma |
1.8% |
| Lymphocytic Leukaemia |
1.8% |
| Prophylaxis |
1.6% |
| Hypertension |
1.4% |
| Juvenile Arthritis |
1.4% |
| B Precursor Type Acute Leukaemia |
1.3% |
| Chronic Myeloid Leukaemia |
1.3% |
| Anxiety |
1.2% |
|
| Drug Hypersensitivity |
33.9% |
| Drug Ineffective |
9.5% |
| Osteonecrosis |
5.3% |
| Rash |
4.8% |
| Toxicity To Various Agents |
4.2% |
| Vomiting |
4.2% |
| Rheumatoid Arthritis |
3.7% |
| Alopecia |
3.2% |
| Pneumonia |
3.2% |
| Pyrexia |
3.2% |
| Bone Marrow Failure |
2.6% |
| Drug Effect Decreased |
2.6% |
| Drug Interaction |
2.6% |
| Hepatic Enzyme Increased |
2.6% |
| Nausea |
2.6% |
| Sepsis |
2.6% |
| Thrombocytopenia |
2.6% |
| Drug Intolerance |
2.1% |
| Leukoencephalopathy |
2.1% |
| Malaise |
2.1% |
|
| Secondary |
| Rheumatoid Arthritis |
44.0% |
| Product Used For Unknown Indication |
7.1% |
| Drug Use For Unknown Indication |
7.0% |
| Acute Lymphocytic Leukaemia |
6.5% |
| Adult T-cell Lymphoma/leukaemia |
4.3% |
| Psoriatic Arthropathy |
3.8% |
| Hypertension |
3.2% |
| T-cell Lymphoma Stage Iv |
3.2% |
| Burkitt's Lymphoma |
3.1% |
| Central Nervous System Lymphoma |
2.4% |
| Prophylaxis |
2.4% |
| Juvenile Arthritis |
2.0% |
| Pain |
1.8% |
| Osteoporosis |
1.8% |
| Diffuse Large B-cell Lymphoma |
1.4% |
| T-cell Lymphoma |
1.3% |
| Non-hodgkin's Lymphoma |
1.2% |
| Psoriasis |
1.2% |
| Depression |
1.2% |
| Still's Disease Adult Onset |
1.1% |
|
| Neutropenia |
10.5% |
| Vomiting |
6.4% |
| Weight Decreased |
6.4% |
| Sepsis |
6.0% |
| Rheumatoid Arthritis |
5.8% |
| Thrombocytopenia |
5.8% |
| Interstitial Lung Disease |
4.9% |
| Pneumonia |
4.9% |
| Pyrexia |
4.7% |
| Drug Hypersensitivity |
4.5% |
| Drug Ineffective |
4.5% |
| Pulmonary Fibrosis |
4.5% |
| Basal Cell Carcinoma |
4.3% |
| Nausea |
4.3% |
| Septic Shock |
4.3% |
| Hepatic Enzyme Increased |
4.1% |
| Spinal Fracture |
3.8% |
| Stomatitis |
3.8% |
| Urinary Tract Infection |
3.4% |
| Viith Nerve Paralysis |
3.2% |
|
| Concomitant |
| Rheumatoid Arthritis |
41.0% |
| Drug Use For Unknown Indication |
24.9% |
| Product Used For Unknown Indication |
10.7% |
| Hypertension |
3.3% |
| Psoriatic Arthropathy |
3.2% |
| Osteoporosis |
2.3% |
| Pain |
2.1% |
| Prophylaxis |
1.7% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.5% |
| Vitamin Supplementation |
1.3% |
| Juvenile Arthritis |
1.1% |
| Ankylosing Spondylitis |
1.1% |
| Psoriasis |
0.9% |
| Crohn's Disease |
0.8% |
| Depression |
0.8% |
| Diabetes Mellitus |
0.7% |
| Polyarthritis |
0.7% |
| Coronary Artery Disease |
0.7% |
| Constipation |
0.6% |
| Prophylaxis Against Graft Versus Host Disease |
0.6% |
|
| Weight Decreased |
10.0% |
| Pyrexia |
9.3% |
| Sepsis |
8.6% |
| Rheumatoid Arthritis |
7.9% |
| Pneumonia |
7.0% |
| Vomiting |
7.0% |
| Urinary Tract Infection |
5.6% |
| Tuberculosis |
4.9% |
| Thrombocytopenia |
4.0% |
| Weight Increased |
4.0% |
| Myocardial Infarction |
3.7% |
| Pulmonary Embolism |
3.7% |
| Respiratory Failure |
3.7% |
| Sinusitis |
3.5% |
| Death |
3.3% |
| Syncope |
3.0% |
| Osteonecrosis |
2.8% |
| Pain |
2.8% |
| Dyspnoea |
2.6% |
| Malignant Melanoma |
2.6% |
|
| Interacting |
| Rheumatoid Arthritis |
31.4% |
| Product Used For Unknown Indication |
30.2% |
| Infection |
6.5% |
| Pain |
3.6% |
| Psoriatic Arthropathy |
3.0% |
| Chemotherapy |
2.4% |
| Hypothyroidism |
2.4% |
| Leukaemia |
2.4% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
2.4% |
| Acute Lymphocytic Leukaemia |
1.8% |
| Candidiasis |
1.8% |
| Essential Hypertension |
1.8% |
| Psoriasis |
1.8% |
| Respiratory Tract Infection |
1.8% |
| Contraception |
1.2% |
| Diabetes Mellitus |
1.2% |
| Febrile Neutropenia |
1.2% |
| Nail Psoriasis |
1.2% |
| Osteosarcoma |
1.2% |
| Smoking Cessation Therapy |
1.2% |
|
| Drug Interaction |
15.9% |
| Drug Level Increased |
11.4% |
| Toxicity To Various Agents |
11.4% |
| White Blood Cell Count Decreased |
9.1% |
| Inappropriate Schedule Of Drug Administration |
6.8% |
| Psoriasis |
6.8% |
| Supraventricular Tachycardia |
6.8% |
| Epistaxis |
4.5% |
| Pancytopenia |
4.5% |
| Headache |
2.3% |
| Liver Function Test Abnormal |
2.3% |
| Pleural Effusion |
2.3% |
| Pruritus |
2.3% |
| Pulmonary Fibrosis |
2.3% |
| Pyrexia |
2.3% |
| Renal Failure Acute |
2.3% |
| Renal Necrosis |
2.3% |
| Rheumatoid Nodule |
2.3% |
| Scleroderma |
2.3% |
|
